[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Idiopathic Pulmonary Fibrosis Ongoing Global Clinical Trials Analysis and Outlook

June 2018 | 106 pages | ID: IB0D9C6E421EN
VPAResearch

US$ 630.00 US$ 700.00 -10 %
Offer valid until December 31, 2024!

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Idiopathic Pulmonary Fibrosis ongoing clinical trials report from VPA Research provides comprehensive analysis and trends in global Idiopathic Pulmonary Fibrosis disease clinical trials. The research work analyzes the ongoing Idiopathic Pulmonary Fibrosis clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Idiopathic Pulmonary Fibrosis treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Idiopathic Pulmonary Fibrosis clinical trials.

Scope of the Report-
  • Ongoing Idiopathic Pulmonary Fibrosis clinical trials across regions
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Idiopathic Pulmonary Fibrosis
  • Both observational and interventional trials analyzed
  • Leading companies and universities participating in Idiopathic Pulmonary Fibrosis clinical trials
Reasons to Buy
  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market
1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 KEY FINDINGS, 2018

2.1 Snapshot
2.2 Overview of Idiopathic Pulmonary Fibrosis Trials

3 CLINICAL TRIALS TRENDS TO 2022

3.1 Ongoing Idiopathic Pulmonary Fibrosis Trials by Phase
3.2 Ongoing Idiopathic Pulmonary Fibrosis Trials by Type
3.3 Ongoing Idiopathic Pulmonary Fibrosis Trials by Recruitment Status

4 COUNTRY LEVEL ANALYSIS

4.1 Region wise Ongoing Idiopathic Pulmonary Fibrosis Trials
4.2 Top 10 Countries conducting Idiopathic Pulmonary Fibrosis Trials
4.3 Trials in Emerging and Developing Economies

5 COMPANY LEVEL ANALYSIS

5.1 Ongoing Idiopathic Pulmonary Fibrosis Trials by Sponsor Type
5.2 Idiopathic Pulmonary Fibrosis Subjects by Sponsor Type
5.3 Subjects Recruited by Leading Sponsors

6 ENROLMENT TRENDS TO 2022

6.1 Subjects Recruited for Idiopathic Pulmonary Fibrosis Trials by year
6.2 Subjects Recruited for Idiopathic Pulmonary Fibrosis Trials by Phase
6.3 Subjects Recruited for Idiopathic Pulmonary Fibrosis Trials by Trial Type
6.4 Subjects Recruited for Idiopathic Pulmonary Fibrosis Trials by Recruitment Status

7 ONGOING TRIALS- PHASE, ID, TITLE, LOCATION, TYPE, DURATION, RECRUITMENT STATUS, COMPANY DETAILS

7.1 Ongoing Idiopathic Pulmonary Fibrosis Trials- Phase
7.2 Ongoing Idiopathic Pulmonary Fibrosis Trials- Phase
7.3 Ongoing Idiopathic Pulmonary Fibrosis Trials- Phase
7.4 Ongoing Idiopathic Pulmonary Fibrosis Trials- Phase

8 APPENDIX

8.1 Abbreviations and Definitions
8.2 Sources and Research Methodology

LIST OF FIGURES

Figure 1: Idiopathic Pulmonary Fibrosis- Clinical Trials by Country
Figure 2: Idiopathic Pulmonary Fibrosis- Clinical Trials by Phase of Development, 2018
Figure 3: Idiopathic Pulmonary Fibrosis- Clinical Trials by Status, 2018
Figure 4: Idiopathic Pulmonary Fibrosis- Clinical Trials by Type, 2018
Figure 5: Idiopathic Pulmonary Fibrosis- Clinical Trials Split by Region, 2000-2018
Figure 6: Idiopathic Pulmonary Fibrosis- Clinical Trials by Type of Economy, 2018
Figure 7: Idiopathic Pulmonary Fibrosis- Enrolment by Phase, 2018
Figure 8: Idiopathic Pulmonary Fibrosis- Enrolment by Trial Type, 2018
Figure 9: Idiopathic Pulmonary Fibrosis- Enrolment by Recruitment Status, 2018
Figure 10: Idiopathic Pulmonary Fibrosis- Clinical Trials by Sponsor Type, 2018
Figure 11: Idiopathic Pulmonary Fibrosis- Enrolment by Type of Sponsors
Figure 12: Idiopathic Pulmonary Fibrosis- Enrolment by Leading Sponsors

LIST OF TABLES

Table 1: Idiopathic Pulmonary Fibrosis- Clinical Trials by Sponsor Type, 2018
Table 2: Idiopathic Pulmonary Fibrosis- Clinical Trials by Economy Type, 2018
Table 3: Idiopathic Pulmonary Fibrosis- Clinical Trials by Region, 2018
Table 4: Idiopathic Pulmonary Fibrosis- Clinical Trial Participations of Top 10 Countries, 2018
Table 5: Idiopathic Pulmonary Fibrosis- Clinical Trials in Emerging and Developing Economies, 2018
Table 6: Idiopathic Pulmonary Fibrosis- Ongoing Phase 1 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 7: Idiopathic Pulmonary Fibrosis- Ongoing Phase 2 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 8: Idiopathic Pulmonary Fibrosis- Ongoing Phase 3 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 9: Idiopathic Pulmonary Fibrosis- Ongoing Phase 4 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company


More Publications